Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
Endocrinology and Metabolism
;
: 53-62, 2019.
Artigo
em Inglês
| WPRIM
| ID: wpr-739219
ABSTRACT
The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Acromegalia
/
Somatostatina
/
Octreotida
/
Cobertura do Seguro
/
Consenso
/
Prova Pericial
/
Seguro Saúde
Tipo de estudo:
Guia de Prática Clínica
/
Pesquisa qualitativa
Idioma:
Inglês
Revista:
Endocrinology and Metabolism
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS